Novartis

JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
JPMHC 2022
Novartis
Leqvio
drug launches
Regeneron
Amgen
Sanofi
Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?
Endpoints
Mon, 01/10/22 - 11:31 pm
Novartis
Molecular Partners
clinical trials
COVID-19
antivirals
ensovibep
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
Fierce Pharma
Mon, 01/10/22 - 11:38 am
JPMHC 2022
Bristol Myers Squibb
Revlimid
Novartis
Moderna Therapeutics
JNJ
Trikafta
Novartis turns to Alnylam in research deal aimed at liver failure
BioPharma Dive
Thu, 01/6/22 - 10:57 am
Novartis
Alnylam Pharmaceuticals
liver failure
Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play
Endpoints
Wed, 01/5/22 - 10:47 pm
Teva Pharmaceutical
Novartis
Sandoz
generics
Narcan
Emergent BioSolutions
Novartis blocks generic to MS blockbuster Gilenya in US patent dispute
Pharmaforum
Tue, 01/4/22 - 10:50 am
Novartis
Gilenya
patents
HEC Pharma
generics
multiple sclerosis
MS
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
Forbes
Mon, 01/3/22 - 10:42 am
Novartis
inclisiran
Leqvio
cholesterol
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents
Pharmaceutical Business Review
Sun, 12/26/21 - 11:17 pm
Novartis
FDA
Cosentyx
arthritis
pediatric
2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in
Fierce Pharma
Wed, 12/22/21 - 11:37 pm
COVID-19
pandemic
remote work
Sanofi
Biogen
Pfizer
Novartis
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
BioPharma Dive
Wed, 12/22/21 - 11:35 pm
Novartis
FDA
Leqvio
cholesterol
Novartis to acquire Gyroscope Therapeutics, gaining ocular gene therapy
Biopharma Reporter
Wed, 12/22/21 - 11:16 am
Novartis
Gyroscope Therapeutics
ocular gene therapy
gene therapy
M&A
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Pharmaforum
Mon, 12/20/21 - 11:01 am
Novartis
ligelizumab
clinical trials
chronic spontaneous urticaria
Xolair
Go or no go? Roche’s fresh start for a new year
EP Vantage
Mon, 12/20/21 - 10:59 am
FDA
Roche
Novartis
Pfizer
AstraZeneca
Cibinqo
Lynparza
Tezspire
Vyvgart
faricimab
Novartis Deepens BeiGene Oncology Pact, Posts Disappointing Results in CSU
BioSpace
Mon, 12/20/21 - 10:49 am
Novartis
BeiGene
China
ociperlimab
anti-TIGIT
Mesoblast considers plans for COVID treatment after Novartis exits deal
Biopharma Reporter
Mon, 12/20/21 - 10:48 am
Mesoblast
Novartis
clinical trials
COVID-19
Mesoblast pummelled as Novartis exits COVID deal
Pharmaforum
Tue, 12/14/21 - 10:42 am
Novartis
Mesoblast
stem cells
remestemcel-L
COVID-19
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Novartis works on pan-coronavirus pill, eyes 2022 human testing
Fierce Biotech
Thu, 12/9/21 - 11:01 am
Novartis
pan-coronavirus pill
COVID-19
drug development
Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024
Endpoints
Mon, 12/6/21 - 10:52 am
Novartis
generics
Entresto
A startup led by Novartis veteran raises $80M to develop gene therapies for the brain
BioPharma Dive
Thu, 12/2/21 - 12:15 pm
AviadoBio
gene therapy
Novartis
Lisa Deschamps
neurodegenerative disease

Pages